Pharmacokinetic Interaction¶
Locate a drug-interaction failure at the exposure layer — one substance altering another's absorption, distribution, metabolism, or excretion so its concentration-time profile shifts at an unchanged dose — rather than as opposition at a shared receptor.
Core Idea¶
Pharmacokinetic interaction is the pattern in which one substance alters a second's disposition — its absorption, distribution, metabolism, or excretion — so the affected agent's concentration-versus-time profile shifts and its effect changes, even at an unchanged dose. It operates at the exposure layer, not the effect layer: the agents do not oppose at a shared receptor (pharmacodynamic antagonism); one perturbs how much of the other is present and for how long, structured by the four ADME stages.
Scope of Application¶
Lives across the subfields of drug-disposition pharmacology; its reach is within that substrate, the body's ADME chemistry.
- Clinical prescribing — interaction databases flagging disposition interactions at the point of care.
- Drug development — required DDI studies with in-vitro CYP and transporter screens.
- Toxicology and forensic pharmacology — cause-of-death attribution (methadone with a CYP inhibitor).
- Therapeutic drug monitoring — re-dosing narrow-index agents like warfarin and tacrolimus.
Clarity¶
Naming an interaction pharmacokinetic localises the failure to the exposure layer, so the correction follows: dose, timing, or substitution. It replaces the helpless "why is this drug behaving differently?" with the tractable "which ADME stage was perturbed, and does the shift matter at this drug's index?" It also makes legible an asymmetry lumping hides: inhibition and induction run on opposite clocks — inhibition bites within hours, induction builds over days and lingers.
Manages Complexity¶
The full combinatorial hazard of co-prescription is far too large to navigate pairwise. The concept compresses it along the four ADME stages, factors the metabolism stage through the shared enzyme pool (one inhibited isoform implicates a whole column of co-substrates), reduces kinetics to one inhibition-versus-induction axis fixing the clock, and gates the whole question against the therapeutic index — dismissing most of the space because the affected drug's window absorbs the shift.
Abstract Reasoning¶
The lead move is ADME-stage identification, from which the corrective lever follows. The decisive predictive move is the inhibition-versus-induction clock, forecasting the sign, onset, and lingering tail of the exposure shift, with a cross-substrate corollary routed through the shared enzyme pool. The boundary-drawing therapeutic-index gate decides whether any of it matters and dismisses most of the space. A reclassifying move separates disposition interaction from pharmacodynamic antagonism.
Knowledge Transfer¶
Within drug-disposition pharmacology the concept transfers as mechanism and densely — the four-stage classification, CYP/transporter grids, inhibition-induction clock, and index gate are the same machinery across prescribing, development, toxicology, and monitoring, and across what perturbs (drug, food, supplement all act through one chemistry). Beyond pharmacology the verdict is metaphor, not mechanism: the literal ADME machinery is irreducibly biological. Only a thin "upstream perturbs downstream-consumed flow" shape survives, better carried by the parents Flow, Pipeline, and Reservoir-Flux Network (and descriptive PK/PD Modeling (Pharmacokinetics / Pharmacodynamics)); the ADME and enzyme furniture stays home. dag_edges:
Relationships to Other Abstractions¶
Current abstraction Pharmacokinetic Interaction Domain-specific
Parents (6) — outgoing typed relations
-
Pharmacokinetic Interaction is a kind of Pharmacological Interaction Domain-specific
Pharmacokinetic Interaction is a strict specialization of Pharmacological Interaction.
-
Pharmacokinetic Interaction presupposes, conditional Absorption Phase Domain-specific
Absorption-stage Pharmacokinetic Interactions presuppose the entry phase whose rate or surviving fraction a food, formulation, or co-agent perturbs.
-
Pharmacokinetic Interaction presupposes, conditional Elimination Pathway Domain-specific
Metabolism- and excretion-stage Pharmacokinetic Interactions presuppose the Elimination Pathway whose rate or route is induced, inhibited, or competed for.
-
Pharmacokinetic Interaction includes, conditional Enzyme Induction Domain-specific
The slow metabolism branch of Pharmacokinetic Interaction contains Enzyme Induction as the capacity-building mechanism that lowers co-substrate exposure.
-
Pharmacokinetic Interaction includes, conditional Enzyme Inhibition Domain-specific
The fast metabolism branch of Pharmacokinetic Interaction contains Enzyme Inhibition as the existing-catalyst block that raises co-substrate exposure.
-
Pharmacokinetic Interaction presupposes Pipeline Prime
Pharmacokinetic Interaction presupposes the staged ADME pipeline that lets a perturbation be localized to absorption, distribution, metabolism, or excretion.
Children (1) — abstractions linked here by typed relations
-
Polypharmacy Domain-specific includes, conditional Pharmacokinetic Interaction
Polypharmacy conditionally contains Pharmacokinetic Interaction as the ADME- layer channel where one regimen member shifts another's exposure.
Hierarchy paths (14) — routes to 11 parentless roots
- Pharmacokinetic Interaction → is a kind of Pharmacological Interaction → includes, typical Synergy and Antagonism → is a kind of Nonlinearity
- Pharmacokinetic Interaction → includes, conditional Enzyme Induction → is a decomposition of Adaptation
- Pharmacokinetic Interaction → presupposes, conditional Absorption Phase → includes Bioavailability
- Pharmacokinetic Interaction → is a kind of Pharmacological Interaction → is a decomposition of Coupling
- Pharmacokinetic Interaction → presupposes Pipeline → is a kind of Decomposition
- Pharmacokinetic Interaction → presupposes, conditional Absorption Phase → includes Flow
- Pharmacokinetic Interaction → presupposes, conditional Elimination Pathway → includes Flow
- Pharmacokinetic Interaction → includes, conditional Enzyme Inhibition → is a kind of Inhibition
- Pharmacokinetic Interaction → presupposes Pipeline → presupposes Iteration
- Pharmacokinetic Interaction → presupposes, conditional Elimination Pathway → includes Receptor Saturation → is a kind of Boundedness
- Pharmacokinetic Interaction → presupposes, conditional Elimination Pathway → includes Receptor Saturation → is a kind of Constraint
- Pharmacokinetic Interaction → presupposes Pipeline → presupposes Modularity → is a kind of, typical Decomposition
- Pharmacokinetic Interaction → presupposes, conditional Elimination Pathway → includes, conditional Metabolic Inactivation → includes Clearance Rate → is a decomposition of Flow
- Pharmacokinetic Interaction → presupposes, conditional Elimination Pathway → includes, conditional Metabolic Inactivation → is a kind of Transformation → is a kind of, typical Function (Mapping)
Neighborhood in Abstraction Space¶
Pharmacokinetic Interaction sits in a moderately populated region (50th percentile for distinctiveness): it has near-neighbors but no dense thicket of look-alikes.
Family — Drug Action & Receptor Pharmacology (16 abstractions)
Nearest neighbors
- Pharmacodynamics — 0.88
- Pharmacodynamic Antagonism — 0.86
- Efficacy — 0.85
- Metabolic Inactivation — 0.85
- Adverse Drug Reaction — 0.85
Computed from structural-signature embeddings · 2026-10-25